×
About 5,333 results

ALLMedicine™ Polycythemia Vera Center

Research & Reviews  2,517 results

Combined venous and arterial thrombosis revealing underlying myeloproliferative disorde...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885597
Journal of Medical Case Reports; Benmalek R, Mechal H et. al.

Feb 17th, 2021 - Myeloproliferative neoplasms (MPNs) such as polycythemia Vera (PV) and Essential Thrombocythemia (ET) can be associated with a high risk of both venous and arterial thrombosis. However, the co-existence between these two complications is very rare...

IMPACT OF COMORBIDITIES AND BODY MASS INDEX ON THE OUTCOME OF POLYCYTHEMIA VERA PATIENTS.
https://doi.org/10.1002/hon.2843
Hematological Oncology; Benevolo G, Elli EM et. al.

Feb 16th, 2021 - In 816 patients with 2016 WHO-defined polycythemia vera (PV) enrolled in a multicenter retrospective study, we investigated the predictive value of Charlson Comorbidity Index (CCI) and body mass index (BMI) on thrombosis, progression to post-PV my...

How do I…perform therapeutic phlebotomy?
https://doi.org/10.1111/trf.16308
Transfusion Peedin AR, Karp JK

Feb 13th, 2021 - Therapeutic phlebotomy (TP) is a well-established medical intervention that evolved from the historical practice of bloodletting. Patients who require TP are not infrequently told by their health-care providers to "just go donate blood," but TP sh...

A systematic review of antithrombotic treatment of venous thromboembolism in patients w...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805324
Blood Advances; Hamulyák EN, Daams JG et. al.

Feb 11th, 2021 - Patients with myeloproliferative neoplasms (MPNs), polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have an increased risk of thrombosis. Risk of recurrent thrombosis can be reduced with antithrombotic therapy and/or cytore...

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated wit...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871138
Blood Cancer Journal; Barbui T, De Stefano V et. al.

Feb 10th, 2021 - In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15...

see more →

Guidelines  11 results

U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
https://ir.celgene.com/press-releases/press-release-details/2019/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis/default.aspx

Aug 16th, 2019 - Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or ...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 6th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018
http://www.jnccn.org/content/15/10/1193.full
Mesa, R.,et al

Sep 30th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh.

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Onco...
https://doi.org/10.6004/jnccn.2016.0169
Journal of the National Comprehensive Cancer Network : JN... Mesa R, Jamieson C et. al.

Dec 13th, 2016 - Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagn...

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/14/12/1572.full
Mesa, R.,et al

Nov 30th, 2016 - Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs). The diagn.

see more →

Drugs  4 results see all →

Clinicaltrials.gov  2,633 results

Combined venous and arterial thrombosis revealing underlying myeloproliferative disorde...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885597
Journal of Medical Case Reports; Benmalek R, Mechal H et. al.

Feb 17th, 2021 - Myeloproliferative neoplasms (MPNs) such as polycythemia Vera (PV) and Essential Thrombocythemia (ET) can be associated with a high risk of both venous and arterial thrombosis. However, the co-existence between these two complications is very rare...

IMPACT OF COMORBIDITIES AND BODY MASS INDEX ON THE OUTCOME OF POLYCYTHEMIA VERA PATIENTS.
https://doi.org/10.1002/hon.2843
Hematological Oncology; Benevolo G, Elli EM et. al.

Feb 16th, 2021 - In 816 patients with 2016 WHO-defined polycythemia vera (PV) enrolled in a multicenter retrospective study, we investigated the predictive value of Charlson Comorbidity Index (CCI) and body mass index (BMI) on thrombosis, progression to post-PV my...

How do I…perform therapeutic phlebotomy?
https://doi.org/10.1111/trf.16308
Transfusion Peedin AR, Karp JK

Feb 13th, 2021 - Therapeutic phlebotomy (TP) is a well-established medical intervention that evolved from the historical practice of bloodletting. Patients who require TP are not infrequently told by their health-care providers to "just go donate blood," but TP sh...

A systematic review of antithrombotic treatment of venous thromboembolism in patients w...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805324
Blood Advances; Hamulyák EN, Daams JG et. al.

Feb 11th, 2021 - Patients with myeloproliferative neoplasms (MPNs), polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have an increased risk of thrombosis. Risk of recurrent thrombosis can be reduced with antithrombotic therapy and/or cytore...

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated wit...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871138
Blood Cancer Journal; Barbui T, De Stefano V et. al.

Feb 10th, 2021 - In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15...

see more →

News  161 results

Fast Five Quiz: Test Your Knowledge on Key Aspects of Heart Failure
https://reference.medscape.com/viewarticle/893861_2

Feb 6th, 2020 - Because of increased myocardial oxygen consumption and demand beyond a critical level, the following high-output states can precipitate the clinical presentation of heart failure: Profound anemia Thyrotoxicosis Myxedema Paget disease of bone Albri...

Weight Gain, Hypertension Seen With Ruxolitinib
https://www.staging.medscape.com/viewarticle/921469

Nov 17th, 2019 - Real-world data from a retrospective study suggest that patients who are taking ruxolitinib (Jakafi, Incyte), which is approved for the treatment of myeloproliferative neoplasms such as polycythemia vera and myelofibrosis, experience weight gain t...

Weight Gain, Hypertension Seen With Ruxolitinib
https://www.medscape.com/viewarticle/921469

Nov 17th, 2019 - Real-world data from a retrospective study suggest that patients who are taking ruxolitinib (Jakafi, Incyte), which is approved for the treatment of myeloproliferative neoplasms such as polycythemia vera and myelofibrosis, experience weight gain t...

Hematocrit (HCT) Levels and Thrombotic Events Among US Veterans With Polycythemia Vera
https://www.mdedge.com/fedprac/avaho/article/207808/hematology/hematocrit-hct-levels-and-thrombotic-events-among-us?channel=53
Kambhampati S, Parasuraman S et. al.

Sep 9th, 2019 - Background: Thrombotic events (TEs) are a leading cause of death in patients with polycythemia vera (PV), contributing to lower overall survival compared with age/sex-matched controls. This analysis evaluated the relationship between HCT levels an.

U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
https://ir.celgene.com/press-releases/press-release-details/2019/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis/default.aspx

Aug 16th, 2019 - Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or ...

see more →

Patient Education  7 results see all →